CARISMA Therapeutics (CARISMA Therapeutics) Debt-to-Equity : 0.69 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics Debt-to-Equity?

CARISMA Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.86 Mil. CARISMA Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.63 Mil. CARISMA Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $10.90 Mil. CARISMA Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 0.69.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CARISMA Therapeutics's Debt-to-Equity or its related term are showing as below:

CARM' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.72 Med: 0.08 Max: 0.69
Current: 0.69

During the past 4 years, the highest Debt-to-Equity Ratio of CARISMA Therapeutics was 0.69. The lowest was -2.72. And the median was 0.08.

CARM's Debt-to-Equity is ranked worse than
80.76% of 1076 companies
in the Biotechnology industry
Industry Median: 0.15 vs CARM: 0.69

CARISMA Therapeutics Debt-to-Equity Historical Data

The historical data trend for CARISMA Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics Debt-to-Equity Chart

CARISMA Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.10

0.23

-0.26

0.12

CARISMA Therapeutics Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial							0.06	0.08	0.06	0.12	0.69

Competitive Comparison of CARISMA Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, CARISMA Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Debt-to-Equity falls into.

CARISMA Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CARISMA Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.935	+	1.188)	/	26.532
	=	0.12

CARISMA Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.864	+	3.628)	/	10.895
	=	0.69

CARISMA Therapeutics (NAS:CARM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CARISMA Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics (CARISMA Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (NAS:CARM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

W2J:Germany

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.carismatx.com

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Executives

Modernatx, Inc.	10 percent owner	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach	director	21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly	director, officer: President and CEO	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris	officer: Chief Financial Officer	397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Michael Klichinsky	officer: Chief Scientific Officer	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bjorn Odlander	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Minori Rosales	officer: Chief Development Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Jewett Michael A. S.	director	C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Peter Honig	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Patricia M. Drake	officer: Chief Commercial Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Elly Ryu	officer: Principal Accounting Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142